These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 34916356)

  • 21. Palatal mucormycosis in a patient with SARS-CoV-2 infection.
    Venugopal A; Marya A
    CMAJ; 2021 Aug; 193(32):E1254. PubMed ID: 34400485
    [No Abstract]   [Full Text] [Related]  

  • 22. The mucormycosis epidemic within COVID-19 pandemic- lessons from India.
    Jy Ong J; Cy Chan A; Sharma AK; Sharma S; Sharma VK
    Brain Behav Immun; 2021 Oct; 97():4-5. PubMed ID: 34371133
    [No Abstract]   [Full Text] [Related]  

  • 23. The rise of mucormycosis in Covid-19 patients in India.
    Bhatia M
    Expert Rev Anti Infect Ther; 2022 Feb; 20(2):137-138. PubMed ID: 34304680
    [No Abstract]   [Full Text] [Related]  

  • 24. Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave?
    Raut A; Huy NT
    Lancet Respir Med; 2021 Aug; 9(8):e77. PubMed ID: 34090607
    [No Abstract]   [Full Text] [Related]  

  • 25. Rhizopus homothallicus: An emerging pathogen in era of COVID-19 associated mucormycosis.
    Kaur H; Kanaujia R; Rudramurthy SM
    Indian J Med Microbiol; 2021; 39(4):473-474. PubMed ID: 34266698
    [No Abstract]   [Full Text] [Related]  

  • 26. Mucormycosis or black fungus infection is a new scare in South Asian countries during the COVID-19 pandemic: Associated risk factors and preventive measures.
    Rahman FI; Islam MR; Bhuiyan MA
    J Med Virol; 2021 Dec; 93(12):6447-6448. PubMed ID: 34260073
    [No Abstract]   [Full Text] [Related]  

  • 27. Mucormycosis in India: unique features.
    Chakrabarti A; Singh R
    Mycoses; 2014 Dec; 57 Suppl 3():85-90. PubMed ID: 25187095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using artificial intelligence-based models to predict the risk of mucormycosis among COVID-19 survivors: An experience from a public hospital in India.
    Syed-Abdul S; Babu AS; Bellamkonda RS; Itumalla R; Acharyulu G; Krishnamurthy S; Ramana YVS; Mogilicharla N; Malwade S; Li YC
    J Infect; 2022 Mar; 84(3):351-354. PubMed ID: 34953910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention of mucormycosis in COVID-19 - the need of the hour.
    Ish P; Ish S
    Indian J Ophthalmol; 2021 Jul; 69(7):1969. PubMed ID: 34146076
    [No Abstract]   [Full Text] [Related]  

  • 30. COVID-19 associated rhino-orbital-cerebral mucormycosis: An observational study from Eastern India, with special emphasis on neurological spectrum.
    Dubey S; Mukherjee D; Sarkar P; Mukhopadhyay P; Barman D; Bandopadhyay M; Pandit A; Sengupta A; Das S; Ghosh S; Adhikari S; Biswas PS; Pal P; Roy H; Patra N; Das A; Sinha P; Mondal MK; Shrivastava SR; Bhattacharya K; Mukhopadhyay M; Ahmed K; Halder TK; Saha M; Ahmed K; Maity S; Mandal A; Chatterjee D; Saha S; Chunakar A; Saha A; Ray BK
    Diabetes Metab Syndr; 2021; 15(5):102267. PubMed ID: 34509790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. COVID-19, DM and Mucormycosis: Prevention is a Mother of Cure.
    Bawaskar HS
    J Assoc Physicians India; 2022 Feb; 70(2):11-12. PubMed ID: 35436838
    [No Abstract]   [Full Text] [Related]  

  • 32. Nasal Microbiota Imbalance as a Contributory Link in the Emergence of COVID-19 Associated Mucormycosis.
    Singh R; Kumari A
    ACS Infect Dis; 2021 Aug; 7(8):2211-2213. PubMed ID: 34328718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mucor in a Viral Land: A Tale of Two Pathogens.
    Sen M; Lahane S; Lahane TP; Parekh R; Honavar SG
    Indian J Ophthalmol; 2021 Feb; 69(2):244-252. PubMed ID: 33463566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors associated with the mucormycosis epidemic during the COVID-19 pandemic.
    Bhanuprasad K; Manesh A; Devasagayam E; Varghese L; Cherian LM; Kurien R; Karthik R; Deodhar D; Vanjare H; Peter J; Michael JS; Thomas M; Samuel P; Varghese GM
    Int J Infect Dis; 2021 Oct; 111():267-270. PubMed ID: 34450284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Posaconazole against Rhizopus oryzae Infection in Silkworm.
    Kurakado S; Matsumoto Y; Sugita T
    Med Mycol J; 2021; 62(3):53-57. PubMed ID: 34471035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rampant Increase in Cases of Mucormycosis in India and Pakistan: A Serious Cause for Concern during the Ongoing COVID-19 Pandemic.
    Ghazi BK; Rackimuthu S; Wara UU; Mohan A; Khawaja UA; Ahmad S; Ahmad S; Hasan MM; Dos Santos Costa AC; Ahmad S; Essar MY
    Am J Trop Med Hyg; 2021 Aug; 105(5):1144-1147. PubMed ID: 34460426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A look into the relationship between outdated coronavirus disease 2019 (COVID-19) treatment protocols and the overwhelming rise of mucormycosis in COVID-19 patients in India.
    Jamal SA; Rayapati A
    Infect Control Hosp Epidemiol; 2022 Nov; 43(11):1733-1735. PubMed ID: 34446122
    [No Abstract]   [Full Text] [Related]  

  • 38. Mass urine sugar testing to tackle post-COVID mucormycosis epidemic in India-MUSTARD concept.
    Garg P; Mittal S
    Diabetes Metab Syndr; 2021; 15(4):102177. PubMed ID: 34198108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overdiagnosis and overtreatment during the covid-19 pandemic.
    Devnani M
    BMJ; 2021 Nov; 375():n2688. PubMed ID: 34759004
    [No Abstract]   [Full Text] [Related]  

  • 40. Mixed mold infection with
    Bellanger AP; Navellou JC; Lepiller Q; Brion A; Brunel AS; Millon L; Berceanu A
    Infect Dis Now; 2021 Oct; 51(7):633-635. PubMed ID: 33527098
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.